Nascent Pharma Holdings EBIT

The latest EBIT for NASC is $-9.6M as of September 2024. That compares with $-9.3M in the prior-year period — down 3.0% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Nascent Pharma Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, NASC's EBIT moved from $-9.3M to $-9.6M — a 3.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nascent Pharma Holdings's operating scale or balance-sheet position.

Against Healthcare companies, NASC currently prints $-9.6M for EBIT, while the sector average sits near $22B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Nascent Pharma Holdings's growth, margins, and balance sheet.

A EBIT figure of $-9.6M for NASC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting NASC's EBIT ($-9.6M), review year-over-year change from $-9.3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.